Financhill
Sell
32

HRTX Quote, Financials, Valuation and Earnings

Last price:
$1.60
Seasonality move :
11.9%
Day range:
$1.56 - $1.61
52-week range:
$1.04 - $3.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.74x
P/B ratio:
--
Volume:
702.6K
Avg. volume:
5M
1-year change:
-11.73%
Market cap:
$240.3M
Revenue:
$127M
EPS (TTM):
-$0.16

Analysts' Opinion

  • Consensus Rating
    Heron Therapeutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, Heron Therapeutics has an estimated upside of 279.75% from its current price of $1.58.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.58.

Fair Value

  • According to the consensus of 0 analysts, Heron Therapeutics has 279.75% upside to fair value with a price target of -- per share.

HRTX vs. S&P 500

  • Over the past 5 trading days, Heron Therapeutics has underperformed the S&P 500 by -6.98% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Heron Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Heron Therapeutics has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Heron Therapeutics reported revenues of $32.8M.

Earnings Growth

  • Heron Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Heron Therapeutics reported earnings per share of -$0.03.
Enterprise value:
343.9M
EV / Invested capital:
2.56x
Price / LTM sales:
1.74x
EV / EBIT:
--
EV / Revenue:
2.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-35.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$99.4M
Return On Assets:
-12.62%
Net Income Margin (TTM):
-20.31%
Return On Equity:
--
Return On Invested Capital:
-20.08%
Operating Margin:
-13.59%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $98.3M $122.8M $137.7M $31.4M $32.8M
Gross Profit $45.1M $55M $99.4M $13.2M $23.4M
Operating Income -$207.8M -$120.8M -$25.9M -$24.9M -$4.5M
EBITDA -$205.4M -$122.7M -$19.4M -$24.2M -$3.9M
Diluted EPS -$2.10 -$0.96 -$0.16 -$0.17 -$0.03
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $351M $315.1M $223.8M $194M $195.2M
Total Assets $390M $352.4M $272M $229.2M $220.8M
Current Liabilities $97.6M $72.3M $93.9M $79.7M $85.5M
Total Liabilities $112.9M $233.5M $249.5M $257M $260.8M
Total Equity $277.1M $118.8M $22.5M -$27.8M -$40M
Total Debt $6.6M $149M $149.2M $173.5M $174.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$154.6M -$98.8M -$8.3M -$9.2M $3.4M
Cash From Investing -$29.6M $28.9M -$1.5M -$23.2M $4M
Cash From Financing $75.1M $54.3M $716K $53.8M $14K
Free Cash Flow -$156.4M -$100.5M -$9.6M -$10M $2.9M
HRTX
Sector
Market Cap
$240.3M
$46.1M
Price % of 52-Week High
40.2%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-11.73%
-30.52%
Beta (5-Year)
1.675
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $1.60
200-day SMA
Sell
Level $2.41
Bollinger Bands (100)
Sell
Level 1.45 - 2.09
Chaikin Money Flow
Sell
Level -33.3M
20-day SMA
Buy
Level $1.52
Relative Strength Index (RSI14)
Buy
Level 52.12
ADX Line
Sell
Level 19.32
Williams %R
Neutral
Level -71.4286
50-day SMA
Buy
Level $1.56
MACD (12, 26)
Buy
Level 0.03
25-day Aroon Oscillator
Buy
Level 32
On Balance Volume
Neutral
Level 60.2M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-11.8179)
Sell
CA Score (Annual)
Level (-4.7799)
Buy
Beneish M-Score (Annual)
Level (-3.6539)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.7631)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Stock Forecast FAQ

In the current month, HRTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRTX average analyst price target in the past 3 months is --.

  • Where Will Heron Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Heron Therapeutics share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Heron Therapeutics?

    Analysts are divided on their view about Heron Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Heron Therapeutics is a Sell and believe this share price will drop from its current level to --.

  • What Is Heron Therapeutics's Price Target?

    The price target for Heron Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is HRTX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Heron Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of HRTX?

    You can purchase shares of Heron Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Heron Therapeutics shares.

  • What Is The Heron Therapeutics Share Price Today?

    Heron Therapeutics was last trading at $1.60 per share. This represents the most recent stock quote for Heron Therapeutics. Yesterday, Heron Therapeutics closed at $1.58 per share.

  • How To Buy Heron Therapeutics Stock Online?

    In order to purchase Heron Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 25

Power Solutions International [PSIX] is up 27.42% over the past day.

Buy
65
TSLL alert for Dec 25

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
75
SMLR alert for Dec 25

Semler Scientific [SMLR] is up 15.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock